CAS Number4311-88-0
Synonyms5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone; Necrostatin-1; 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxoimidazolidin-4-one; Necrostatin 1; MTH-trp; 5-indol-3-ylmethyl-3-methyl-2-thioxo-imidazolidin-4-one; Nec-1
Molecular FormulaC13H13N3OS
Molecular Weight259.33
Purity≥98 (HPLC)%
Density1.4±0.1 g/cm3
Boiling Point441.9±37.0 °C at 760 mmHg
Melting Point151ºC
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 4311-88-0 |
| Catalog No. | 2A-9082781 |
| Chinese Name | Necrostatin-1 |
| Synonyms | 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone; Necrostatin-1; 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxoimidazolidin-4-one; Necrostatin 1; MTH-trp; 5-indol-3-ylmethyl-3-methyl-2-thioxo-imidazolidin-4-one; Nec-1 |
| Molecular Formula | C13H13N3OS |
| Molecular Weight | 259.33 |
| Purity | ≥98 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 441.9±37.0 °C at 760 mmHg |
| Melting Point | 151ºC |
| Appearance | powder |
| Water Solubility | DMSO: >10 mg/mL |
| Storage Condition | −20°C |
| Application | Necrostatin-1 is a potent, selective and cell-permeable inhibitor of necroptosis with an EC50 of 490 nM in Jurkat cells. It acts by inhibiting the death domain receptor kinase RIP (RIP1) in the necrop |
| HTC | 2933990090 |
| PubChem ID | 24724559 |
| MDL Number | MFCD00056916 |
| SMILES | CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O |
| InChI | 1S/C13H13N3OS/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,11,14H,6H2,1H3,(H,15,18) |
| InChI Key | TXUWMXQFNYDOEZ-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | transportation |
| MSDS | msds/82781_1_4311_88_0.pdf |
| Bioactivity | Necrostatin-1 is a potent, selective and cell-permeable necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. It acts by inhibiting the death domain kinase RIP (RIP1) in the necroptosis pathway. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Apoptosis >> RIP kinase Research Areas >> Cancer Target RIP1 kinase[1] In Vitro Necrostatin-1 (Nec-1) is a specific and potent small-molecule inhibitor of cell death caused by death-domain receptor (DR) stimulation in the presence of caspase inhibition in multiple cell types. Necrostatin-1 efficiently inhibits the TNFα-induced necrotic death of L929 cells, which does not require exogenous caspase inhibitors[1]. Necrostatin-1 (Nec-1) prevents radiocontrast media (RCM)-induced dilation of peritubular capillaries, suggesting a novel role unrelated to cell death for the RIP1 kinase domain in the regulation of microvascular hemodynamics and pathophysiology of contrast-induced AKI (CIAKI)[2]. The decreased viability of C6 glioma cells caused by 3.0 µM and 6.0 µM shikonin is improved by pretreatment with Necrostatin-1 (Nec-1) to 92.3% and 82.9% at 1.5 h and 84.4% and 78.6% at 3.0 h, respectively. Similarly, the viability of U87 glioma cells is elevated by Necrostatin-1 to 91.6% and 81.5% at 1.5 h, and 81.8% and 71.2% at 3.0 h, respectively[3]. Necrostatin-1 (Nec-1) (30 µM) increases the survival of cardiomyocyte progenitor cell (CMPCs) by inhibiting necrotic cell death[4]. In Vivo Necrostatin-1 (Nec-1) induces tubular bilation and affects the kinetics of the dilation of peritubular capillaries after RCM application. Upon a single intraperitoneal application of a single dose of Necrostatin-1 (1.65 mg/kg body weight, i.p.) 15 minutes before RCM, the return to baseline levels is prevented within the observation period[2]. Cell Assay C6 (3×105 cells/well) and U87 (1.5×105 cells/well) glioma cells are seeded onto 96-well microplate and cultured 24 h. PBS is added into the control group and Shikonin is added into experimental group to reach the final concentration. Cellular viability is assessed using an MTT assay after Shikonin treatment at indicated time point. The absorbance value (A) at 570 nm is read using an automatic multi-well spectrophotometer. Two groups of glioma cells from the same cell line are treated with Shikonin at lower or higher concentration, respectively; other two groups of glioma cells are treated 1 h with 100 µM Necrostatin-1 or 40 µM z-VAD-fmk prior to co-incubation with Shikonin at indicated concentration. Additionally, another two groups of glioma cells are treated only with 100 µM Necrostatin-1 or 40 µM Z-VAD-fmk at corresponding time point[3]. Animal Admin Mice[2] 8-10 week old male C57BL/6 mice (average weight approx.23 g) are used. Mice receive intravenous application of 200 μL PBS or radiocontrast media (RCM) via the tail vein. A single dose of Z-VAD-fmk (10 mg/kg body weight) or Necrostatin-1 (1.65 mg/kg body weight) is applied intraperitoneally 15 min. before RCM-injection. Mice are harvested another 24 hours after RCM-application (48 hours after reperfusion). Blood samples are obtained from retroorbital bleeding and serum levels of urea and creatinine are determined. References [1]. Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1(2):112-9. [2]. Linkermann A, et al. The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013 Oct;24(10):1545-57. [3]. Huang C, et al. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One. 2013 Jun 28;8(6):e66326. [4]. Feyen D, et al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013 Jul 1;99(1):83-91. [5]. Zhou K, et al. RIP1-RIP3-DRP1 pathway regulates NLRP3 inflammasome activation following subarachnoid hemorrhage. Exp Neurol. 2017 Sep;295:116-124. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 441.9±37.0 °C at 760 mmHg Melting Point 151ºC Molecular Formula C13H13N3OS Molecular Weight 259.327 Flash Point 221.1±26.5 °C Exact Mass 259.077942 PSA 80.22000 LogP 1.26 Appearance of Characters solid Vapour Pressure 0.0±1.1 mmHg at 25°C Index of Refraction 1.738 InChIKey TXUWMXQFNYDOEZ-UHFFFAOYSA-N SMILES CN1C(=O)C(Cc2c[nH]c3ccccc23)NC1=S Storage condition −20°C Water Solubility DMSO: >10 mg/mL |
| Use of | Necrostatin-1 is a potent, selective and cell-permeable necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. It acts by inhibiting the death domain kinase RIP (RIP1) in the necroptosis pathway. Properties Name 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one Synonym More Synonyms Necrostatin-1 Biological Activity Description Necrostatin-1 is a potent, selective and cell-permeable necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. It acts by inhibiting the death domain kinase RIP (RIP1) in the necroptosis pathway. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Apoptosis >> RIP kinase Research Areas >> Cancer RIP1 kinase[1] References [1]. Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1(2):112-9. [2]. Linkermann A, et al. The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013 Oct;24(10):1545-57. [3]. Huang C, et al. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One. 2013 Jun 28;8(6):e66326. [4]. Feyen D, et al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013 Jul 1;99(1):83-91. [5]. Zhou K, et al. RIP1-RIP3-DRP1 pathway regulates NLRP3 inflammasome activation following subarachnoid hemorrhage. Exp Neurol. 2017 Sep;295:116-124. Chemical & Physical Properties Molecular Formula C13H13N3OS Exact Mass 259.077942 PSA 80.22000 Appearance of Characters solid Index of Refraction 1.738 InChIKey TXUWMXQFNYDOEZ-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 99.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Nutritional Ingredients | ||
|---|---|---|
| N-Benzoyl-L-arginineamidehydrochloride | 4299-03-0 | 2A-9082617 |
| N-Benzoyl-L-argininemethylesterhydrochloride | 1784-04-9 | 2A-9082619 |
| N-Benzoyl-L-argininep-nitroanilidehydrochloride | 21635-40-7 | 2A-9082621 |
| Glycyl-L-tyrosinehydrate | 207300-83-2 | 2A-9082630 |
| p-Nitro-L-phenylalanine | 95753-55-2 | 2A-9082633 |
| PTH-DL-tryptophan | 5789-24-2 | 2A-9082785 |
| 5-Fluoro-DL-tryptophan | 154-08-5 | 2A-9082866 |
| 5-Hydroxy-L-Tryptophan,hydroxhloride | 17469-40-8 | 2A-9082879 |
| Acetyl-L-tryptophanamide | 2382-79-8 | 2A-9082894 |
| 1-Methyl-L-tryptophan | 526-31-8 | 2A-9082941 |
| Browse all Nutritional Ingredients products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS